Gilead Sciences, Inc. with ticker code (GILD) have now 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $117.00 and $67.00 calculating the mean target price we have $81.29. Now with the previous closing price of $64.92 this is indicating there is a potential upside of 25.2%. It’s also worth noting that there is a 50 day moving average of $69.92 while the 200 day moving average is $75.78. The company has a market cap of 80.46B. The current share price for the company is: $64.58 USD
The potential market cap would be $100,744,743,925 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 179.39, revenue per share of $22.00 and a 10.63% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
